Acadia Pharmaceuticals (ACAD) Cash & Equivalents (2010 - 2026)

Acadia Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $282.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 29.64% year-over-year to $282.2 million in Q1 2026; TTM through Mar 2026 was $282.2 million, a 29.64% increase from a year earlier, with the FY2025 full-year figure at $177.7 million, down 44.4% from the prior year.
• Cash & Equivalents improved to $282.2 million in Q1 2026 per ACAD's latest filing, from $177.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $319.6 million in Q4 2024 and bottomed at $98.2 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $188.7 million (2023), against an average of $196.8 million.
• Across the five-year window, Cash & Equivalents plunged 47.62% in 2022 and soared 69.4% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $114.8 million in 2022, then surged by 64.27% to $188.7 million in 2023, then surged by 69.4% to $319.6 million in 2024, then plunged by 44.4% to $177.7 million in 2025, then jumped by 58.82% to $282.2 million in 2026.
• Per Business Quant, the three latest ACAD Cash & Equivalents figures stand at $282.2 million (Q1 2026), $177.7 million (Q4 2025), and $258.0 million (Q3 2025).